Viyash Scientific LtdNSE:VIYASH
Current view Q4 2026
Merging two drug firms nearly tripled profit margins and grew profit 14-fold - management delivered early and honestly. A real, proven turnaround; only catch is the pricey stock.
Latest exchange filings last 5 · 5 after Q4 2026
- 18 Sep ’26Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS 18 Sep ↗
- 8 Sep ’26Italian FDI/Golden Power approval received for BioForLife Italia acquisition; completion expected within two months. ↗
- 4 Sep ’26Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS 4 Sep ↗
- 27 Aug ’26Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 27 Aug ↗
- 16 Aug ’26Announcement under Regulation 30 (LODR)-Earnings Call Transcript 16 Aug ↗
Exchange filings, with the company's own one-line summary, read off the same page as the figures. Screener publishes only the most recent few, so this is the last 5 — not everything filed since your note, and a quiet-looking list is not proof of a quiet quarter. A filing is marked new when it is dated after the end of the quarter your note covers. Not scored, and not a judgement — a routine repayment notice and a takeover sit in the same list.
AI concall report · Q4 2026
The full earnings-call read behind this view — what management promised, what they delivered, and the earning trigger.
Growth Q4 2026
| Metric | This year vs lastYoY · vs Q4 2025 | vs the quarter beforeQoQ, sequential · vs Q3 2026 | 3-year yearly average3Y CAGR · compounded | 5-year yearly average5Y CAGR · compounded |
|---|---|---|---|---|
| Sales | ▲ +128.9% | +7.2% | +34.0% | +20.2% |
| Operating profit | ▲ +300.0% | +4.5% | +443.0% | +25.2% |
| EPS | ▲ +221.6% | +35.2% | +128.0% | +1.1% |
| PAT | ▲ +560.0% | +34.7% | — | — |
Tinted rows drive the Tier. Tier = the weaker of YoY Sales and YoY PAT growth. Here the weaker is Sales at +128.9%, which is ≥ 20% → Tier 1.
QoQ is sequential, not a trend. For most Indian companies the March quarter is seasonally the largest, so a June-quarter fall against it is a calendar effect. Only the YoY column feeds the Tier.
Multibagger potential
Good65/100
Cheap, and growing fast. Profit per share grew 60% a year, while the price-tag on its earnings actually got smaller. That gap — real growth nobody has paid up for — is exactly what this score looks for.
₹241 → ₹482 needs the P/E at 21× — it is 44× today, and has ranged 47× to 898× over the last 5 years. The rest would come from earnings growing as they have.
What you pay for its profitlog scale · 5-year range
Tripling needs 32× — below anything it traded at in 5 years.
Target capped at 60× — its 198× five-year average came from near-zero earnings.
At ₹331 the price-tag on its earnings reaches the 60× it is being projected toward — the point where being cheap against that yardstick is used up.
Growth rate is a one-off base reset — the score can't be trusted. Check next quarter.
How this is calculated
This is arithmetic, not a forecast — Return = ΔEPS × ΔMultiple. It says what would have to be true, not how likely it is, and "earnings keep growing at this rate for three more years" is the assumption doing the most work. This is a mid-cap at ₹10,511 cr, so the odds of a re-rate are not fighting its own size.
Why the target is capped at 60×. This company averaged 198× over five years, but a multiple that high comes from near-zero earnings rather than from what buyers chose to pay — projecting a return to it would price in the collapse, not the recovery. 60× is what a 60% grower supports.
Growth rate used: 60.0% — the weakest of EPS / Sales / Op-profit from 3-year EPS CAGR, capped at 60%. Latest quarter reads 60%.
How it compares with its rivals Healthcare · 6 of 159 listed
These are the industry's largest names rather than companies of its own size, so the columns are worth reading straight across — a ranking against them would only be restating the size gap.
| Company | Price | P/E | Size | ROCE | Profitlast qtr | Saleslast qtr |
|---|---|---|---|---|---|---|
| Viyash Scientific | ₹249 | 49.5× | ₹10,973 Cr | 13.4% | +103.6% | +19.5% |
| Sun Pharma.Inds. | ₹1,853 | 35.1× | ₹4.45 L Cr | 20.5% | +6.0% | +10.5% |
| Divi's Lab. | ₹9,379 | 83.5× | ₹2.49 L Cr | 22.0% | +65.5% | +27.8% |
| Torrent Pharma. | ₹4,855 | 82.8× | ₹1.85 L Cr | 15.2% | +5.8% | +54.9% |
| Zydus Lifesci. | ₹1,152 | 23.6× | ₹1.15 L Cr | 21.1% | −35.1% | +22.0% |
| Cipla | ₹1,375 | 31.0× | ₹1.11 L Cr | 15.5% | −39.2% | +2.3% |
Screener's own peer group, from the request already made for the industry P/E. It serves the industry's largest names by market cap, not companies of a similar size, so treat this as context rather than a like-for-like table; this company is always shown. On a phone the price, size and sales columns are dropped rather than pushed off the edge. Not part of the score.
Business quality to Jun 2026
| Are the margins widening? | yes — widening, and steadily | operating margin -2% → 19% over 3 years |
|---|---|---|
| Did the profit turn into cash? | most of it, with some tied up | 59% last year, 78% over three · free cash flow ₹225 cr, positive in 3 of 5 years |
| Is the growth borrowed? | lightly borrowed | ₹490 cr — 0.17× its own equity (was 0.27×) |
| Is it being collected? | collection is steady | 112 days to collect, up 14 in a year · cash cycle 160 days |
| Who has been buying? | the promoters have been buying | promoters 61.3% (+8.7 in a year), 52.8% → 61.3% over 2.8 years · FIIs 4.5% (−1.6) · DIIs 3.8% (−9.2) · shareholders 1,84,521 → 1,28,367 |
| What does it earn on its capital? | earns a fair return on its capital | ROCE 13.4% · ROE 7.4% |
Fetched from the filings, not typed — and deliberately not part of the score. These are the questions the score cannot ask: it reads growth, price and trend, so a company can score well while its profit never becomes cash. Weigh these beside the note, not against the number.
Screener's own checklist not mine, not the score
In its favour
- Company has reduced debt.
- Company is expected to give good quarter
Against it
- Stock is trading at 3.71 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 3.80% over last 3 years.
- Working capital days have increased from 71.6 days to 111 days
Generated by screener.in from a fixed checklist — not written by me and not an input to the score. It is here as a second machine opinion to weigh against the note; where it disagrees with the view above, the note is the considered one.